This program is supported by Novartis Pharmaceuticals Corporation. Content is independently developed by CMSC.
Mark Freedman, MD, MSc, Tanuja Chitnis, MD, and Ahmed Obeidat, MD, PhD, discuss the role of biomarkers and the key areas in which they will be used in managing day-to-day decisions in patient management.
Mark S. Freedman, MD, MSc, hosts a webinar on using serum neurofilament for managing multiple sclerosis (MS). He introduces Tanuja Chitnis, MD, a neurology professor at Harvard Medical School, and Dr Ahmed Obeidat, MD, PhD, an associate professor of neurology at the Medical College of Wisconsin.
The focus of the discussion is on serum neurofilament light chain as a tool in evaluating and managing MS patients. Mark Freedman, MD, MSc, emphasizes the need for clinically useful blood biomarkers in MS management.
The conversation shifts to the value of biomarkers in MS management. Tanuja Chitnis, MD highlights the potential of biomarkers in providing insights into biological factors, aiding in early diagnosis, detecting inflammatory activity, assessing treatment response, and predicting long-term patient outcomes.
The discussion delves into neurofilament light chain specificity for MS diagnosis. Tanuja Chitnis, MD acknowledges its non-specific nature, elevated in various neurological diseases, but emphasizes its potential role in improving the diagnosis when combined with other criteria, citing scenarios where highly elevated levels, lesions, and clinical features may support an earlier MS diagnosis.
Video synopsis is AI-generated and reviewed by HCPLive® editorial staff.